

May 8, 2023

Kidswell Bio Corporation

Code: 4584 (Growth Market, TSE)

Masaharu Tani, President & CEO

Announcement of presentation on basic research results of SHED at American Society of Gene & Cell Therapy (ASGCT)

Tokyo, May 8, 2023 – Kidswell Bio Corporation (KWB) will present the basic research results of SHED at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) from May 16 to 20 at Los Angeles, CA, in the U.S. This conference is an annual meeting organized by ASGCT, and doctors and researchers from all over the world participate every year, presenting many research results related to gene and cell therapy.

KWB will make the following two presentations as the results of basic research on the characteristics of SHED manufacturing.

Presentation 1

Comparative Analysis of Gene Expression and Growth Factor Secretion in Stem Cells from Human Exfoliated Deciduous Teeth (SHED) and Other Tissue-Derived Mesenchymal Stem Cells: Therapeutic Potential with SHED for Neurological Diseases.

Presentation 2

Stem Cells from Human Exfoliated Deciduous Teeth (SHED) Obtained by a Serum-Free Method Induced Significant Angiogenesis and Restored Blood Flow in a Rat Model of Critical Limb Ischemia.

For more information about the ASGCT 26th Annual Meeting, please see the following website.

<https://annualmeeting.asgct.org>

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com